Clinical Trial Update: Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating neoadjuvant chemotherapy with Myocet, Taxotere, and Herceptin for HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Myocet (liposomal doxorubicin)
• Taxotere (docetaxel)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED